Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.07 USD
Change Today +0.09 / 3.02%
Volume 8.4K
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

roka bioscience inc (ROKA) Snapshot

Open
$2.86
Previous Close
$2.98
Day High
$3.07
Day Low
$2.86
52 Week High
07/18/14 - $13.00
52 Week Low
05/1/15 - $2.85
Market Cap
55.4M
Average Volume 10 Days
25.5K
EPS TTM
$-2.93
Shares Outstanding
18.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROKA BIOSCIENCE INC (ROKA)

Related News

No related news articles were found.

roka bioscience inc (ROKA) Related Businessweek News

No Related Businessweek News Found

roka bioscience inc (ROKA) Details

Roka Bioscience, Inc., a molecular diagnostics company, focuses on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens in the United States. It provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include molecular tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin- producing E.coli, and Listeria monocytogenes, as well as related consumable supplies. It serves food processors, third-party contract testing laboratories, and government regulatory authorities. The company was founded in 2009 and is based in Warren, New Jersey.

110 Employees
Last Reported Date: 03/27/15
Founded in 2009

roka bioscience inc (ROKA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $583.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $371.6K
Senior Vice President and General Manager
Total Annual Compensation: $371.6K
Compensation as of Fiscal Year 2014.

roka bioscience inc (ROKA) Key Developments

Roka Bioscience, Inc. Reports Unaudited Earnings Results for Fourth Quarter and Year Ended December 31, 2014

Roka Bioscience, Inc. reported unaudited earnings results for fourth quarter and year ended December 31, 2014. For the quarter, the company’s revenue was $1,356,000 against $689,000 a year ago. Loss from operations was $8,850,000 against $7,443,000 a year ago. Loss before income tax was $9,411,000 against $7,601,000 a year ago. Net loss and comprehensive loss was $7,431,000 against $4,473,000 a year ago. Basic and diluted net loss per common share was $0.43 against $7.51 a year ago. The increase in fourth quarter revenue year-on-year resulted from an increase in the number of Atlas® instruments placed with commercial customers and increased commercial utilization of the instruments. For the year, the company’s revenue was $5,057,000 against $2,182,000 a year ago. Loss from operations was $31,592,000 against $29,637,000 a year ago. Loss before income tax was $34,182,000 against $32,670,000 a year ago. Net loss and comprehensive loss was $32,230,000 against $29,578,000 a year ago. Basic and diluted net loss per common share was $2.93 against $56.81 a year ago.

Roka Bioscience, Inc. Announces Board Changes

Josh Bilenker, M.D. resigned from the Board of Directors of Roka Bioscience, Inc., effective immediately, due to demands on his time and other professional commitments, including his role as Chief Executive Officer and director of Loxo Oncology, Inc. Dr. Bilenker indicated that his resignation was not the result of any disagreement with the Company on any matters relating to the Company's operations, policies or practices. At the time of his resignation, Dr. Bilenker served on the audit committee. Effective immediately, the Company appointed M. James Barrett to its audit committee.

Roka Bioscience, Inc. to Report Q4, 2014 Results on Mar 26, 2015

Roka Bioscience, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Mar 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROKA:US $3.07 USD +0.09

ROKA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $159.02 USD +1.34
Bio-Rad Laboratories Inc $137.08 USD +2.12
BioMerieux €96.85 EUR +1.07
EI du Pont de Nemours & Co $74.03 USD -0.01
Neogen Corp $43.62 USD +0.80
View Industry Companies
 

Industry Analysis

ROKA

Industry Average

Valuation ROKA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.1x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROKA BIOSCIENCE INC, please visit www.rokabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.